Search Result

Isoforms Recommended:	Abl

Results for "

Abl

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bcr-Abl (181) AAK1 (1) Ack1 (1) Akt (4) Antibiotic (1) Apoptosis (45) Aurora Kinase (12) Autophagy (40) Bacterial (1) Bcl-2 Family (1) BCRP (1) c-Fms (2) c-Kit (17) c-Met/HGFR (1) c-Myc (1) CaMK (1) Casein Kinase (1) Caspase (1) CDK (2) Collagen (1) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (1) Deubiquitinase (1) Discoidin Domain Receptor (4) DNA/RNA Synthesis (1) Drug Metabolite (9) E3 Ligase Ligand-Linker Conjugates (1) EGFR (4) Ephrin Receptor (3) ERK (1) Ferroptosis (2) FGFR (8) FLT3 (14) Fluorescent Dye (1) HDAC (1) Histone Methyltransferase (1) IGF-1R (1) Isotope-Labeled Compounds (11) JAK (10) Ligands for E3 Ligase (8) Ligands for Target Protein for PROTAC (7) LIM Kinase (LIMK) (2) MAP4K (2) MAPKAPK2 (MK2) (1) Microtubule/Tubulin (3) Mitosis (3) MNK (1) p38 MAPK (1) Parasite (1) PARP (2) PDGFR (25) Phosphatase (1) PI3K (1) PKD (1) Prion Protein (2) PROTACs (9) Raf (4) Reference Standards (15) RET (4) Salt-inducible Kinase (SIK) (2) SARS-CoV (8) Small Interfering RNA (siRNA) (7) SNIPERs (13) Src (44) STAT (9) TAM Receptor (3) Thymidylate Synthase (1) Tyrosinase (1) ULK (2) VEGFR (11) Wee1 (1)
By Research Areas:	Cancer (207) Cardiovascular Disease (2) Endocrinology (1) Infection (8) Inflammation/Immunology (6) Metabolic Disease (1) Neurological Disease (12)
Oligonucleotides:	Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (3) siRNAs (7)

236

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: Bcr-Abl

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1785

Abl Cytosolic Substrate Abltide	Bcr-Abl	Cancer
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ). Abl Protein Tyrosine Kinase (AbI) is a truncated form of the v-AbI Protein Tyrosine Kinase, a partner in the Gag-Abl fusion protein of the Abelson murine leukemia virus .

HY-P5426

Abl protein tyrosine kinase substrate	Bcr-Abl	Others
Abl protein tyrosine kinase substrate is a biological active peptide. (Abltide is a peptide substrate for Abl Kinase (Abl protein tyrosine kinase), a partner in the gag-Abl fusion protein of the Abelson murine leukemia virus. Used in Western blot and kinase assay.)

HY-104010A

Asciminib hydrochloride 10+ Cited Publications Abl001 hydrochloride	Bcr-Abl	Cancer
Asciminib (ABL001) hydrochloride is a potent and selective allosteric *BCR-ABL1* inhibitor, which inhibits Ba/F3 cells grown with an IC₅₀ of 0.25 nM .

HY-104010

Asciminib 10+ Cited Publications Abl001	Bcr-Abl	Cancer
Asciminib (ABL001) is a potent and selective allosteric *BCR-ABL1* inhibitor, which inhibits Ba/F3 cells grown with an IC₅₀ of 0.25 nM .

HY-RS00104

ABL1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ABL1 Rat Pre-designed siRNA Set A contains three designed siRNAs for ABL1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

ABL1 Rat Pre-designed siRNA Set A ABL1 Rat Pre-designed siRNA Set A

HY-RS00103

Abl1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Abl1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Abl1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Abl1 Mouse Pre-designed siRNA Set A Abl1 Mouse Pre-designed siRNA Set A

HY-RS00102

ABL1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ABL1 Human Pre-designed siRNA Set A contains three designed siRNAs for ABL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ABL1 Human Pre-designed siRNA Set A ABL1 Human Pre-designed siRNA Set A

HY-135635

ABL-001-Amide-PEG3-acid	Fluorescent Dye	Others
ABL-001-Amide-PEG3-acid, an analogue of ABL-001, is usually used as a labeled chemical or fluorescent probe.

HY-142913

ABL-L	Apoptosis	Cancer
ABL-L induces apoptosis of human laryngocarcinoma cells through p53-dependent pathway.

HY-104010R

Asciminib (Standard) Abl001 (Standard)	Reference Standards Bcr-Abl	Cancer
Asciminib (Standard) is the analytical standard of Asciminib. This product is intended for research and analytical applications. Asciminib (ABL001) is a potent and selective allosteric *BCR-ABL1* inhibitor, which inhibits Ba/F3 cells grown with an IC₅₀ of 0.25 nM .

HY-108317

ABL127	Phosphatase	Cancer
ABL127 is a selective and covalent inhibitor of protein methylesterase 1 (PME-1) with IC₅₀s of 6.4 nM and 4.2 nM in HEK293T and MDA-MB-231 cells, respectively.

HY-RS00105

ABL2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ABL2 Human Pre-designed siRNA Set A contains three designed siRNAs for ABL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ABL2 Human Pre-designed siRNA Set A ABL2 Human Pre-designed siRNA Set A

HY-RS18744

Abl2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Abl2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Abl2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Abl2 Mouse Pre-designed siRNA Set A Abl2 Mouse Pre-designed siRNA Set A

HY-RS25231

Abl2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Abl2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Abl2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Abl2 Rat Pre-designed siRNA Set A Abl2 Rat Pre-designed siRNA Set A

HY-E70639

ABL1 Q252H Recombinant Human Active Protein Kinase	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 Q252H Recombinant Human Active Protein Kinase is a recombinant ABL1 Q252H protein that can be used to study ABL1 Q252H-related functions .

HY-E70640

ABL1 T315I Recombinant Human Active Protein Kinase	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 T315I Recombinant Human Active Protein Kinase is a recombinant ABL1 T315I protein that can be used to study ABL1 T315I-related functions .

HY-E70638

ABL1 M351T Recombinant Human Active Protein Kinase	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 M351T Recombinant Human Active Protein Kinase is a recombinant ABL1 M351T protein that can be used to study ABL1 M351T-related functions .

HY-E70635

ABL1 F317I Recombinant Human Active Protein Kinase	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 F317I Recombinant Human Active Protein Kinase is a recombinant ABL1 F317I protein that can be used to study ABL1 F317I-related functions .

HY-E70641

ABL1 Y253F Recombinant Human Active Protein Kinase	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 Y253F Recombinant Human Active Protein Kinase is a recombinant ABL1 Y253F protein that can be used to study ABL1 Y253F-related functions .

HY-E70636

ABL1 G250E Recombinant Human Active Protein Kinase	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 G250E Recombinant Human Active Protein Kinase is a recombinant ABL1 G250E protein that can be used to study ABL1 G250E-related functions .

HY-E70637

ABL1 H396P Recombinant Human Active Protein Kinase	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 H396P Recombinant Human Active Protein Kinase is a recombinant ABL1 H396P protein that can be used to study ABL1 H396P-related functions .

HY-E70634

ABL1 E255K Recombinant Human Active Protein Kinase	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 E255K Recombinant Human Active Protein Kinase is a recombinant ABL1 E255K protein that can be used to study ABL1 E255K-related functions .

HY-145887

*BCR-ABL1-IN-1*	Bcr-Abl	Cancer
BCR-ABL1-IN-1 (Example 74) is the inhibitor for ABL1 (64-515) with IC₅₀ of 8.7 nM .

HY-169230

*BCR-ABL-IN-9*	Bcr-Abl	Cancer
BCR-ABL-IN-9 (Compound B1) is a *BCR-ABL* inhibitor that achieves sustained *BCR-ABL* suppression by forming stable covalent bonds with the *ABL* kinase. BCR-ABL-IN-9 is also effective in inhibiting the activity of the *ABL* kinase (IC₅₀ = 1.2 nM). BCR-ABL-IN-9 possesses anticancer activity .

HY-111872

*SNIPER(ABL)-020*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein .

HY-111858

*SNIPER(ABL)-050*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-050, conjugating Imatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein .

HY-169231

*BCR-ABL-IN-10*	Bcr-Abl	Cancer
BCR-ABL-IN-10 (compound B4) is a covalent and aryl vinyl sulfate (AVS)-containing *BCR-ABL* inhibitor with an IC₅₀ of 43.1 nM for ABL kinase. BCR-ABL-IN-10 forms a covalent and stable adduct with ABL kinase, leading to sustained inhibition of endogenous BCR-ABL activities. BCR-ABL-IN-10 can be used for the study of chronic myeloid leukemia (CML) .

HY-111851

*SNIPER(ABL)-049*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-049, conjugating Imatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 100 μM .

HY-18819

*BCR-ABL-IN-2*	Bcr-Abl	Cancer
BCR-ABL-IN-2 is an inhibitor of *BCR-ABL1* tyrosine kinase, with IC₅₀s of 57 nM, 773 nm for ABL1 ^native and ABL1 ^T315I, respectively.

HY-126143

*CHMFL-ABL-039*	Bcr-Abl	Cancer
CHMFL-ABL-039 is a type II native *ABL* kinase and drug-resistant V299L mutant *BCR-ABL* inhibitor with the IC₅₀s of 7.9 nM and 27.9 nM, respectively. CHMFL-ABL-039 is used in the research of chronic myeloid leukemia .

HY-111860

*SNIPER(ABL)-013*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-013, conjugating GNF5 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 20 μM .

HY-111859

*SNIPER(ABL)-058*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-058, conjugating Imatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 10 μM .

HY-150566

*BCR-ABL-IN-5*	Bcr-Abl	Cancer
BCR-ABL-IN-5 (compound II) is a *Bcr-Abl* kinase** (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-Abl ^WT and Bcr-Abl ^T3151 with the IC₅₀ value of 0.014 μM and 0.45 μM, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells .

HY-111861

*SNIPER(ABL)-024*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-024, conjugating GNF5 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 5μM .

HY-111873

*SNIPER(ABL)-019*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-019, conjugating Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 0.3 μM .

HY-111854

*SNIPER(ABL)-015*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-015, conjugating GNF5 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 5 μM .

HY-111874

*SNIPER(ABL)-039*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 10 nM. IC₅₀s are 0.54 nM, 10 nM, 12 nM, and 50 nM for *ABL*, cIAP1, cIAP2, XIAP, respectively .

HY-111862

*SNIPER(ABL)-044*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-044, conjugating HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 10 μM .

HY-136526

*BCR-ABL-IN-3*	Bcr-Abl	Cancer
BCR-ABL-IN-3 is a potent and irreversible *Bcr-Abl* inhibitor with an IC₅₀ of ≤100 nM for Ba/F₃Bcr-Abl ^T3151. BCR-ABL-IN-3 has anti-cancer activity .

HY-153008

*BCR-ABL-IN-7*	Bcr-Abl	Cancer
BCR-ABL-IN-7 (compound 4) is a WT and T315I mutant ABL kinases inhibitor. BCR-ABL-IN-7 effectively inhibits activities of WT and T315I mutant ABL kinases. BCR-ABL-IN-7 can be used for the research of chronic myeloid leukemia (CML) research .

HY-150569

*BCR-ABL-IN-6*	Bcr-Abl	Cancer
BCR-ABL-IN-6 (9h) is a selective *Bcr-Abl* kinase inhibitor with IC₅₀s of 4.6 and 227 nM for *Bcr-Abl* ^WT and Bcr-Abl ^T3151** respectively. BCR-ABL-IN-6 inhibits *Bcr-Abl* kinase with strong affinity inside the cells with an EC₅₀ of 14.6 nM. BCR-ABL-IN-6 is an imatinib derivative which can be used for research of chronic myelogenous leukemia . BCR-ABL-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-111863

*SNIPER(ABL)-047*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-047, conjugating HG-7-85-01 (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 2 μM .

HY-119370

*CHMFL-ABL-121*	Bcr-Abl Apoptosis	Cancer
CHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC₅₀s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively .

HY-101268

*CHMFL-ABL-053*	Bcr-Abl Src p38 MAPK	Cancer
CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available *BCR-ABL, SRC* and p38 kinase inhibitor with IC₅₀ values of 70, 90 and 62 nM against ABL1, SRC and p38, respectively .

HY-111871

*SNIPER(ABL)-033*	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-033, conjugating HG-7-85-01 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of *BCR-ABL* protein with a DC₅₀ of 0.3 μM (ABL inhibitor: HY-15814; ABL inhibitor activity control: HY-131178; E3 ligase ligand: HY-128808; linker: HY-130500; E3 ligase ligand + linker: HY-128819) .

HY-101034

*CHMFL-ABL/KIT-155* CHMFL-Abl-KIT-155	Bcr-Abl c-Kit Apoptosis PDGFR Discoidin Domain Receptor	Cancer
CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC₅₀s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC₅₀=81 nM), CSF1R (IC₅₀=227 nM), DDR1 (IC₅₀=116 nM), DDR2 (IC₅₀=325 nM), LCK (IC₅₀=12 nM) and PDGFRβ (IC₅₀=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis .

HY-139730

*c-ABL-IN-1*	Bcr-Abl	Neurological Disease
c-ABL-IN-1 is a novel selective *c-Abl* inhibitor that prevents neurodegeneration in parkinson’s disease.

HY-156148

*BCR-ABL-IN-8*	Bcr-Abl	Cancer
BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor containing trimethoxy group .

HY-142922

*BCR-ABL-IN-4*	Bcr-Abl	Cancer
BCR-ABL-IN-4 is a *BCR-ABL* inhibitor with anticancer effects. BCR-ABL-IN-4 inhibits the cancer cell growth with IC₅₀ values of 0.67 nM and 16 nM for K562 cells and BCR-ABL T315I transfected Ba/F3 cells, respectively (WO2021143927A1; compound 11) .

HY-172096

*cSRC/BCR-ABL-IN-1*	Bcr-Abl Src	Cancer
cSRC/BCR-ABL-IN-1 (compound 21b) is a potent *Bcr-Abl* and C-Src inhibitor with IC₅₀ values of 56.2, 101 nM for Bcr-Abl, C-Src, respectively. cSRC/BCR-ABL-IN-1 shows cytotoxicity activity .

Cat. No.	Product Name

HY-L196

Protein Kinase Compound Library

3,704 compounds

Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR.

MCE designs a unique collection of 3,704 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.

HY-L129

Target Protein Ligand Library

67 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 67 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

HY-L080

Targeted Therapy Drug Library

106 compounds

Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer.

There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases.

MCE carefully collects a unique of 106 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

HY-L016

Protein Tyrosine Kinase Compound Library

1,402 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,402 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L060

Cytoskeleton Compound Library

1,818 compounds

The cytoskeleton is responsible for contraction, cell motility, movement of organelles and vesicles through the cytoplasm, cytokinesis, intracellular signal transduction, and many other functions that are essential for cellular homeostasis and survival. It accomplishes these tasks through three basic structures: F-actin, microtubules, and intermediate filaments (IFs). The cytoskeleton is a dynamic structure where the three major filaments and tubules are under the influence of proteins that regulate their length, state of polymerization, and level of cross-linking. Since cytoskeleton is involved in virtually all cellular processes, cytoskeletal protein aberrations are the underlying reason for many pathological phenotypes, including several cardiovascular disease syndromes, neurodegeneration, cancer, liver cirrhosis, pulmonary fibrosis, and blistering skin diseases.

MCE designs a unique collection of 1,818 cytoskeleton-related compounds mainly focusing on the key targets in the cytoskeleton signal pathway and can be used in the research of cytoskeleton signal pathway and related diseases.

HY-L079

Anti-Blood Cancer Compound Library

3,586 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 3,586 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-135635

ABL-001-Amide-PEG3-acid	Fluorescent Dyes/Probes
ABL-001-Amide-PEG3-acid, an analogue of ABL-001, is usually used as a labeled chemical or fluorescent probe.

HY-15150G

Bemcentinib (GMP)

R428 (GMP); BGB324 (GMP)

Fluorescent Dye

Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

Cat. No.	Product Name	Type

HY-15150G

Bemcentinib (GMP)

R428 (GMP); BGB324 (GMP)

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P1785

Abl Cytosolic Substrate Abltide	Bcr-Abl	Cancer
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ). Abl Protein Tyrosine Kinase (AbI) is a truncated form of the v-AbI Protein Tyrosine Kinase, a partner in the Gag-Abl fusion protein of the Abelson murine leukemia virus .

HY-P5426

Abl protein tyrosine kinase substrate	Bcr-Abl	Others
Abl protein tyrosine kinase substrate is a biological active peptide. (Abltide is a peptide substrate for Abl Kinase (Abl protein tyrosine kinase), a partner in the gag-Abl fusion protein of the Abelson murine leukemia virus. Used in Western blot and kinase assay.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-108486

Herbimycin A	Infection Quinones Structural Classification Microorganisms Classification of Application Fields Source classification Benzene Quinones Disease Research Fields	Bacterial Antibiotic
Herbimycin A, an ansamycin antibiotic, acts as a Src family kinase inhibitor. Herbimycin A binds to the SH domain and inhibits the activity of p60 ^v-src and p210 ^BCR-ABL Herbimycin A inhibits Hsp90 and impairs recovery from heat shock. Herbimycin A exhibits antiangiogenic activity in endothelial cells in vitro.

HY-N14767

Naphthablin	Structural Classification Natural Products Microorganisms Source classification	DNA/RNA Synthesis Bcr-Abl
Naphthablin is a naphthoquinone compound that inhibits *Abl* oncogene functions. Naphthablin inhibits Abl-induced morphological transformation in v-ablts-NIH3T3 cells and inhibits RNA synthesis .

HY-125780R

5-Phenylhydantoin (Standard)	Microorganisms Source classification	Drug Metabolite Reference Standards
Dasatinib (monohydrate) (Standard) is the analytical standard of Dasatinib (monohydrate). This product is intended for research and analytical applications. Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib monohydrate also induces apoptosis and autophagy.

HY-N14635

Paeciloquinone A	Structural Classification Microorganisms Xanthones Source classification Phenols	EGFR
Paeciloquinone A can inhibit EGFR protein tyrosine kinase. Paeciloquinone A inhibits the *V-abl* protein tyrosine kinase with an IC₅₀** of 0.59 μM .

HY-N14637

Paeciloquinone C	Structural Classification Microorganisms Xanthones Source classification Phenols	EGFR
Paeciloquinone C can inhibit the EGFR protein tyrosine kinase. Paeciloquinone C inhibits the V-abl protein tyrosine K_inase with an IC₅₀ of 0.56 μM .

Species:	Human (4) Virus (5)
Tag:	His (6) Tag Free (1) GST (2)
Source:	HEK293 (4) Sf9 insect cells (3) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P71685

	ABL1 Protein, Human (GST) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; Abl; JTK7; p150; Proto oncogene tyrosine protein kinase Abl1	Human	E. coli
	ABL1, Human (GST) is a non-receptor tyrosine-protein kinase. ABL1, Human is implicated in a wide range of cellular processes, including regulation of cell growth and survival, oxidative stress and DNA-damage responses, actin dynamics and cell migration, transmission of information about the cellular environment through integrin signaling.

HY-P77308

	ABL1 Protein, Human (sf9, GST) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; Abl; JTK7; p150; Proto oncogene tyrosine protein kinase Abl1	Human	Sf9 insect cells
	ABL1 is a non-receptor tyrosine protein kinase that coordinates key cellular processes for growth and survival. It affects cytoskeletal remodeling, cell motility, and receptor endocytosis. ABL1 Protein, Human (sf9, GST) is the recombinant human-derived ABL1 protein, expressed by Sf9 insect cells , with N-GST labeled tag.

HY-P702716

	ABL1 Protein, Human (sf9) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; Abl; JTK7; p150; Proto oncogene tyrosine protein kinase Abl1	Human	Sf9 insect cells
	ABL1 is a non-receptor tyrosine protein kinase that coordinates key cellular processes for growth and survival. It affects cytoskeletal remodeling, cell motility, and receptor endocytosis. ABL1 Protein, Human (sf9) is the recombinant human-derived ABL1, expressed by Sf9 insect cells, with tag-free. The total length of ABL1 Protein, Human (sf9) is 1104 a.a..

HY-P705439

	SORBS2 Protein, Human (His) (Arg-binding protein 2)(ArgBP2)(Arg/Abl-interacting protein 2)(Sorbin)	Human	E. coli

HY-P73952

	*HA/Hemagglutinin Protein, Influenza B (ABL77299, HEK293, His)* HA; Hemagglutinin; HA/Hemagglutinin, Influenza B (B/Oita/15/1992, HEK293, His)	Virus	HEK293
	The hemagglutinin (HA) protein attaches viral particles to host cells by binding to sialic acid-containing receptors and induces viral particle internalization through clathrin-dependent endocytosis. HA also promotes an alternative clathrin- and caveolin-independent pathway for some virions. HA/Hemagglutinin Protein, Influenza B (ABL77299, HEK293, His) is the recombinant Virus-derived HA/Hemagglutinin protein, expressed by HEK293 , with C-His labeled tag.

HY-P73953

	*HA/Hemagglutinin Protein, Influenza B (ABL77244, sf9, His)* HA; Hemagglutinin; HA/Hemagglutinin, Influenza B (B/Victoria/02/1987, sf9, His)	Virus	Sf9 insect cells
	The hemagglutinin (HA) protein attaches viral particles to host cells by binding to sialic acid-containing receptors and induces viral particle internalization through clathrin-dependent endocytosis. HA also promotes an alternative clathrin- and caveolin-independent pathway for some virions. HA/Hemagglutinin Protein, Influenza B (ABL77244, sf9, His) is the recombinant Virus-derived HA/Hemagglutinin protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P73954

	*HA1/Hemagglutinin Protein, Influenza B (ABL77244, HEK293, His)* HA; Hemagglutinin; HA/Hemagglutinin, Influenza B (B/Victoria/02/1987, HEK293, His)	Virus	HEK293
	The hemagglutinin (HA) protein attaches viral particles to host cells by binding to sialic acid-containing receptors and induces viral particle internalization through clathrin-dependent endocytosis. HA also promotes an alternative clathrin- and caveolin-independent pathway for some virions. HA/Hemagglutinin Protein, Influenza B (ABL77244, HEK293, His) is the recombinant Virus-derived HA/Hemagglutinin protein, expressed by HEK293 , with C-His labeled tag.

HY-P74912

	*HA1/Hemagglutinin Protein, Influenza B (ABL77255, HEK293, His)* Influenza B (B/Yamagata/16/1988) Hemagglutinin / HA1 Protein (HEK293, His)	Virus	HEK293
	The hemagglutinin HA1 protein is essential for attachment of virions to host cells by binding to sialic acid-containing receptors, inducing virion internalization via clathrin-dependent or clathrin- and caveolin-independent pathways.As a class I viral fusion protein, HA1 determines host range restriction and virulence, mediating fusion between the virion membrane and the endosomal membrane.HA1/Hemagglutinin Protein, Influenza B (ABL77255, HEK293, His) is the recombinant Virus-derived HA1/Hemagglutinin protein, expressed by HEK293 , with C-His labeled tag.

HY-P74913

	*HA1/Hemagglutinin Protein, Influenza B (ABL77101, HEK293, His)* Influenza B (B/Victoria/504/2000) Hemagglutinin / HA1 Protein (HEK293, His)	Virus	HEK293
	The hemagglutinin HA1 protein is essential for attachment of virions to host cells by binding to sialic acid-containing receptors, inducing virion internalization via clathrin-dependent or clathrin- and caveolin-independent pathways.As a class I viral fusion protein, HA1 determines host range restriction and virulence, mediating fusion between the virion membrane and the endosomal membrane.HA1/Hemagglutinin Protein, Influenza B (ABL77101, HEK293, His) is the recombinant Virus-derived HA1/Hemagglutinin protein, expressed by HEK293 , with C-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-12047S

Ponatinib-d8
Ponatinib-d₈ is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-15463S1

Imatinib-d4
Imatinib-d₄ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .

HY-15463S

Imatinib-d8 1 Publications Verification
Imatinib-d₈ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .

HY-13904S

Flumatinib-d3
Flumatinib-d₃ is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC₅₀s of 1.2 nM, 307.6 nM and 665.5 nM, respectively .

HY-10181S

Dasatinib-d8
Dasatinib-d₈ is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.

HY-10159S

Nilotinib-d6
Nilotinib-d₆ is a deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity .

HY-132549S

Nilotinib-d3
Nilotinib-d₃ is the deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity .

HY-15463S2

Imatinib-d3 hydrochloride

Imatinib-d₃ (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

HY-10181S1

Dasatinib-d4

Dasatinib-d₄ (BMS-354825-d₄) is deuterium labeled Dasatinib. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC₅₀s of <1.0 nM and 0.5 nM, respectively . Dasatinib also induces apoptosis and autophagy.

HY-10158S

Bosutinib-d8
Bosutinib-d₈ is a deuterium labeled Bosutinib. Bosutinib is a dual Src/Abl inhibitor with IC₅₀s of 1.2 nM and 1 nM, respectively .

HY-10159S1

Nilotinib-13C,d3
Nilotinib-13C,d3 is a deuterated labeled Nilotinib . Nilotinib is an orally available *Bcr-Abl* tyrosine kinase inhibitor with antineoplastic activity.

HY-15463S3

Imatinib-13C,d3

Imatinib- ¹³C,d₃ (STI571- ¹³C,d₃) is ¹³C labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

HY-133794S

Dasatinib N-oxide-d8
Dasatinib N-oxide-d₈ is the deuterium labeled Dasatinib N-oxide. Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor .

HY-107447S

N-Deshydroxyethyl Dasatinib-d8
N-Deshydroxyethyl Dasatinib-d₈ is the deuterium labeled N-Deshydroxyethyl Dasatinib. N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825), the Dasatinib-based moiety, binds to IAP ligand via a linker to form SNIPER to degrade ABL .

HY-10158S1

Bosutinib-13C,d3
Bosutinib- ¹³C,d₃ (SKI-606- ¹³C,d₃) is ¹³C labeled Bosutinib. Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC₅₀ of 1.2 nM and 1 nM, respectively .

HY-G0017S1

N-Desmethyl imatinib-d4
N-Desmethyl imatinib-d₄ is the deuterium-labeled N-Desmethyl imatinib (HY-G0017). N-Desmethyl imatinib-d₄ (Norimatinib) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .

HY-15728S

Radotinib-d6

Radotinib-d₆ is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC₅₀ of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83458

	ABL2 Antibody (YA3203) Abl2; AblL; ARG; Abelson tyrosine-protein kinase 2; Abelson murine leukemia viral oncogene homolog 2; Abelson-related gene protein; Tyrosine-protein kinase ARG	WB, FC	Human, Mouse, Rat
	ABL2 Antibody (YA3203) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ABL2.

HY-P83095

	ABI2 Antibody (YA2840) Abelson interactor 2; ABI2; ABI2B; Abl binding protein 3; AblBP3; ArgBP1; ARGBPIA; ArgBPIB; SSH3BP2	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	ABI2 Antibody (YA2840) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ABI2.

HY-P86379

	ABL1 Antibody (YA6071) c-Abl; Abl1; Abl; JTK7; Tyrosine-protein kinase Abl1; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; Proto-oncogene c-Abl; p150;	WB, IHC-P, ICC/IF, IP, ELISA	Human
	ABL1 Antibody (YA6071) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ABL1.

HY-P85070

	ABL1 Antibody (YA4762) Abl1; Abl; JTK7; Tyrosine-protein kinase Abl1; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; Proto-oncogene c-Abl; p150	WB, ELISA	Human
	ABL1 Antibody (YA4762) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to ABL1.

HY-P85044

	ABL2 Antibody (YA4736) Abl2; AblL; ARG; Abelson tyrosine-protein kinase 2; Abelson murine leukemia viral oncogene homolog 2; Abelson-related gene protein; Tyrosine-protein kinase ARG	WB, ICC/IF, ELISA	Human, Mouse
	ABL2 Antibody (YA4736) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to ABL2.

HY-P83171

	ETV6 Antibody (YA2916) ETV6; Tel; TEL oncogene; TEL/Abl; TEL1	WB, ICC/IF, FC	Human
	ETV6 Antibody (YA2916) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ETV6.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Abl

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products